Oruka Therapeutics’ (ORKA) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Oruka Therapeutics (NASDAQ:ORKA) in a report released on Thursday morning, MarketBeat.com reports. HC Wainwright currently has a $120.00 price target on the stock.

Several other brokerages have also recently commented on ORKA. Wedbush restated an “outperform” rating and set a $165.00 target price on shares of Oruka Therapeutics in a report on Tuesday, August 11th. UBS Group lifted their price target on Oruka Therapeutics from $100.00 to $130.00 and gave the company a “buy” rating in a report on Wednesday, July 1st. Piper Sandler reiterated an “overweight” rating and set a $180.00 price target on shares of Oruka Therapeutics in a research report on Tuesday, June 2nd. Weiss Ratings raised shares of Oruka Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 15th. Finally, Guggenheim restated a “buy” rating and issued a $200.00 price objective on shares of Oruka Therapeutics in a research report on Tuesday, August 11th. Ten analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $133.00.

Oruka Therapeutics Price Performance

Shares of ORKA opened at $92.51 on Thursday. The company has a market capitalization of $6.13 billion, a P/E ratio of -45.57 and a beta of -0.34. Oruka Therapeutics has a one year low of $14.66 and a one year high of $115.51. The business’s 50 day simple moving average is $95.24 and its 200-day simple moving average is $69.58.

Oruka Therapeutics (NASDAQ:ORKA) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). On average, sell-side analysts anticipate that Oruka Therapeutics will post -2.42 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Lawrence Klein sold 75,000 shares of Oruka Therapeutics stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $91.83, for a total transaction of $6,887,250.00. Following the completion of the sale, the chief executive officer directly owned 925,580 shares of the company’s stock, valued at $84,996,011.40. The trade was a 7.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Carl Dambkowski sold 22,417 shares of the company’s stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $70.13, for a total value of $1,572,104.21. Following the completion of the sale, the director owned 51,326 shares of the company’s stock, valued at $3,599,492.38. This represents a 30.40% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 158,116 shares of company stock valued at $13,523,783 over the last 90 days. Company insiders own 23.49% of the company’s stock.

Institutional Trading of Oruka Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Legal & General Group Plc bought a new position in Oruka Therapeutics during the 2nd quarter worth approximately $28,000. Nykredit A S acquired a new stake in Oruka Therapeutics in the second quarter worth $29,000. BNP Paribas Financial Markets raised its holdings in Oruka Therapeutics by 464.0% in the second quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company’s stock worth $31,000 after purchasing an additional 2,306 shares during the period. Royal Bank of Canada boosted its position in shares of Oruka Therapeutics by 47.2% during the fourth quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock worth $34,000 after purchasing an additional 365 shares in the last quarter. Finally, Los Angeles Capital Management LLC acquired a new position in shares of Oruka Therapeutics in the 4th quarter valued at $37,000. 56.44% of the stock is owned by institutional investors.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.